AMPHHealthcare · Drug Manufacturers - Specialty & GenericThe 7 Wall Street analysts covering Amphastar Pharmaceuticals, Inc. hold a median 12-month price target of $21 — -17.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 6 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Amphastar Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (34): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AMPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −17.8% from it.
Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | Barclays | Maintains | Equal-Weight | $20 → $23 |
| 7 Aug 2026 | Piper Sandler | Maintains | Neutral | — |
| 7 Aug 2026 | Piper Sandler | Maintains | Neutral | $21 → $20 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $19 → $20 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | $25 → $20 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | — |
| 3 June 2026 | Barclays | Maintains | Equal-Weight | — |
| 14 May 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 11 May 2026 | Piper Sandler | Reiterates | Neutral | — |
| 8 May 2026 | Needham | Downgrade | Hold | — |
| 21 Apr 2026 | Jefferies | Downgrade | Hold | — |
| 8 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 27 Feb 2026 | Needham | Maintains | Buy | — |
| 27 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 9 Dec 2025 | Barclays | Initiates | Equal-Weight | — |
| 7 Nov 2025 | Needham | Maintains | Buy | — |
| 22 Oct 2025 | Needham | Reiterates | Buy | — |
| 26 Aug 2025 | B of A Securities | Maintains | Neutral | — |
| 12 Aug 2025 | Needham | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMPH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Amphastar Pharmaceuticals, Inc. returned −1.1% against +17.7% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 45% of US stocks
Cheaper than 59% of US stocks
Cheaper than 56% of US stocks
Cheaper than 46% of US stocks
Higher than 40% of US stocks
Higher than 34% of US stocks
Higher than 63% of US stocks
Higher than 81% of US stocks
Higher than 71% of US stocks
Higher than 64% of US stocks
Higher than 77% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Amphastar Pharmaceuticals, Inc. has a market value of $1.1B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $730.0M. The latest quarter grew 5.4% year on year.
Net income over the same four quarters: $78.5M, a 10.8% net margin.
Diluted earnings per share, trailing twelve months: $1.69.
Free cash flow in the twelve months to 30 June 2026: $152.9M.
Amphastar Pharmaceuticals, Inc. spent $100.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 15.2×; forward P/E: 8.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Amphastar Pharmaceuticals, Inc. employs 1,976 people — $369K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Amphastar Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article discusses Zacks’ approach to identifying stocks, emphasizing its Rank system, earnings estimates, estimate revisions, and value, growth, and momentum trends. The excerpt does not state a specific conclusion about Amphastar Pharmaceuticals.
Why it matters — AMPH watchers can note the article’s screening criteria, but the excerpt offers no company-specific assessment.
Amphastar Pharmaceuticals announced that CFO Bill Peters and EVP of Regulatory Affairs and Clinical Operations Tony Marrs will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, at 4:30 pm ET.
Why it matters — The company's executive participation at a major industry conference provides investors an opportunity to hear directly from leadership about the company's operations and regulatory activities.
Zacks Investment Research highlights the Medical - Generic Drugs industry, noting that it benefits from new product launches, biosimilar momentum, and portfolio shifts despite ongoing pricing pressure and supply chain challenges. The article identifies three generic drug stocks to watch within this improving industry trend.
Why it matters — As a generic drug manufacturer, Amphastar operates within this industry, so the sector-wide trends of new launches and biosimilar growth signal relevant conditions for the company.
Zacks Investment Research added Amphastar Pharmaceuticals, Inc. (AMPH) to its Zacks Rank #5 (Strong Sell) List on August 14, 2026, alongside CHT and HE. The designation reflects a poor near-term outlook assigned by Zacks' ranking system.
Why it matters — AMPH watchers would care because receipt of a Zacks Strong Sell rating indicates a weak near-term assessment from a widely followed research service that could influence investor perception of the stock.
Seeking Alpha published the transcript of Amphastar Pharmaceuticals' Q2 2026 earnings call. The item reports the company's second-quarter 2026 financial results discussion as presented during the earnings call.
Why it matters — The Q2 2026 earnings call transcript provides AMPH investors with a direct account of the company's recent quarterly performance and management commentary.
The 7 Wall Street analysts covering Amphastar Pharmaceuticals, Inc. have a median 12-month price target of $21, with estimates ranging from $20 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Amphastar Pharmaceuticals, Inc., 0 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Amphastar Pharmaceuticals, Inc. 86 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Amphastar Pharmaceuticals, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies -17.8% from the last close, and Ticker Nerd's factor model ranks Amphastar Pharmaceuticals, Inc. 86 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Amphastar Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $30 over the next 12 months.
Amphastar Pharmaceuticals, Inc. returned -1.1% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets technically challenging generic and proprietary injectable, inhalation, and intranasal products.
The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?". The article discusses Zacks’ approach to identifying stocks, emphasizing its Rank system, earnings estimates, estimate revisions, and value, growth, and momentum trends. The excerpt does not state a specific conclusion about Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets technically challenging generic and proprietary injectable, inhalation, and intranasal products. Amphastar Pharmaceuticals, Inc. also supplies active pharmaceutical ingredient products, including insulin APIs, supporting both its own finished medicines and external customers. Its portfolio includes prescription and over-the-counter treatments used in hospital, urgent care, and retail pharmacy settings, with products addressing areas such as respiratory care, allergic reactions, anticoagulation, opioid overdose reversal, and diagnostic support. The company operates through its Pharmaceutical Products segment and emphasizes complex drug delivery systems, biologics, and biosimilar capabilities. Amphastar Pharmaceuticals, Inc. serves healthcare providers, distributors, and patients across the United States and selected international markets.
CEO Dr. Yongfeng Zhang Ph.D. · 1,976 employees · United States · https://www.amphastar.com
